1.
Lebwohl M, Strober B, Scharnitz T, Linaberry M, Hoyt K, Banerjee S, Kisa RM, Martin G. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin [Internet]. 2023Nov.13 [cited 2024Jul.15];7(6):s244. Available from: https://www.jofskin.org/index.php/skin/article/view/2354